{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T03:05:15Z","timestamp":1794711915151,"version":"4.9.1"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pain Res."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Neuropathic pain is a prevalent and burdensome condition, and both pregabalin and gabapentin are widely used for its treatment. However, there is a lack of clarity regarding their comparative efficacy and safety. This meta-analysis aims to evaluate and compare the effectiveness and safety of pregabalin vs. gabapentin in managing neuropathic pain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study followed PRISMA guidelines and employed the PICOS search strategy. Comparative studies (clinical trials and cohort studies) were included, with patients with neuropathic pain treated either with pregabalin or gabapentin. Primary outcomes assessed were efficacy and safety. Data were extracted from PubMed, Embase, Scopus, and the Cochrane Collaboration Library databases. The risk of bias was evaluated using the Cochrane Review Manager tool. Statistical analysis was performed using Review Manager 5.4.1 software, calculating effect sizes and conducting sensitivity analysis based on medication dosage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 14 studies with 3,346 patients were analyzed. Pregabalin showed superior results compared to gabapentin in the Visual Analog Scale (VAS) at various time intervals up to 12\u201314 weeks (SMD \u22120.47, 95% CI \u22120.74 to \u22120.19). The pregabalin group also had significant improvements in SF-12\/SF-36\/EQ-5D scores (SMD 0.39, 95% CI 0.11\u20130.68) and experienced more days with no\/mild pain (MD 9.00, 95% CI 8.93\u20139.07) and fewer days with severe pain (MD \u22123.00, 95% CI \u22124.96 to \u22121.04). Pregabalin resulted in lower opioid consumption (OR 0.50, 95% CI 0.33\u20130.76). Gabapentin had a higher incidence of nausea and vomiting. Sensitivity analysis supported the efficacy of pregabalin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In conclusion, pregabalin demonstrated superior and faster efficacy in alleviating neuropathic pain than gabapentin did. Additionally, it improved patient-reported outcomes, resulted in lower opioid consumption, and led to fewer adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:uri>https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=565208<\/jats:uri>\n                      , PROSPERO (CRD42024565208).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpain.2024.1513597","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T02:19:19Z","timestamp":1736216359000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":40,"title":["Pregabalin vs. gabapentin in the treatment of neuropathic pain: a comprehensive systematic review and meta-analysis of effectiveness and safety"],"prefix":"10.3389","volume":"5","author":[{"given":"V\u00edctor","family":"Mayoral","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Galvez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Ferr\u00e1ndiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xo\u00e1n","family":"Migu\u00e9ns V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Cordero-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Alc\u00e1ntara Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concepci\u00f3n","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"P\u00e9rez-P\u00e1ramo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.neurol.2018.09.016","article-title":"Neuropathic pain: definition, assessment and epidemiology","volume":"175","author":"Bouhassira","year":"2019","journal-title":"Rev Neurol (Paris)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2165\/00019053-200927020-00002","article-title":"Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy","volume":"27","author":"O'Connor","year":"2009","journal-title":"Pharmacoeconomics"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1212\/01.wnl.0000282763.29778.59","article-title":"Neuropathic pain: redefinition and a grading system for clinical and research purposes","volume":"70","author":"Treede","year":"2008","journal-title":"Neurology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.jpain.2009.08.005","article-title":"Impact of postherpetic neuralgia and painful diabetic peripheral neuropathy on health care costs","volume":"11","author":"Dworkin","year":"2010","journal-title":"J Pain"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1053\/j.ajkd.2003.08.025","article-title":"Pain in hemodialysis patients: prevalence, cause, severity, and management","volume":"42","author":"Davison","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1080\/14737175.2016.1202764","article-title":"Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use","volume":"16","author":"Calandre","year":"2016","journal-title":"Expert Rev Neurother"},{"key":"B7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.eplepsyres.2006.09.008","article-title":"Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery","volume":"73","author":"Taylor","year":"2007","journal-title":"Epilepsy Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1002\/nau.23225","article-title":"Gabapentenoids in pain management in urological chronic pelvic pain syndrome: gabapentin or pregabalin?","volume":"36","author":"Agarwal","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"B9","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/papr.12014","article-title":"A randomized, controlled trial of gabapentin enacarbil in subjects with neuropathic pain associated with diabetic peripheral neuropathy","volume":"13","author":"Rauck","year":"2013","journal-title":"Pain Pract"},{"key":"B10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.4103\/0253-7613.91867","article-title":"Evaluation of efficacy and safety of gabapentin, duloxetine, and pregabalin in patients with painful diabetic peripheral neuropathy","volume":"44","author":"Devi","year":"2012","journal-title":"Indian J Pharmacol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.clinthera.2010.07.014","article-title":"Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: findings from a cost-consequences analysis in a nested case-control study","volume":"32","author":"P\u00e9rez","year":"2010","journal-title":"Clin Ther"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1185\/03007995.2013.820694","article-title":"Long-term treatment of anxiety disorders with pregabalin: a 1 year open-label study of safety and tolerability","volume":"29","author":"Montgomery","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"B13","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1111\/j.1528-1167.2010.02532.x","article-title":"Long-term add-on pregabalin treatment in patients with partial-onset epilepsy: pooled analysis of open-label clinical trials","volume":"51","author":"Uthman","year":"2010","journal-title":"Epilepsia"},{"key":"B14","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.pnpbp.2011.10.009","article-title":"Long-term efficacy and safety of gabapentin enacarbil in Japanese restless legs syndrome patients","volume":"36","author":"Inoue","year":"2012","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1111\/j.1499-1654.2000.001592.x","article-title":"Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy","volume":"41","author":"Lhatoo","year":"2000","journal-title":"Epilepsia"},{"key":"B16","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1111\/papr.12516","article-title":"Effects of pregabalin in patients with neuropathic pain previously treated with gabapentin: a pooled analysis of parallel-group, randomized, placebo-controlled clinical trials","volume":"17","author":"Markman","year":"2017","journal-title":"Pain Pract"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1016\/j.apmr.2014.06.010","article-title":"Gabapentinoids are effective in decreasing neuropathic pain and other secondary outcomes after spinal cord injury: a meta-analysis","volume":"95","author":"Mehta","year":"2014","journal-title":"Arch Phys Med Rehabil"},{"key":"B18","first-page":"883","article-title":"Perioperative administration of gabapentin 1,200\u2005mg day-1 and pregabalin 300\u2005mg day-1 for pain following lumbar laminectomy and discectomy: a randomised, double-blinded, placebo-controlled study","volume":"52","author":"Ozgencil","year":"2011","journal-title":"Singapore Med J"},{"key":"B19","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2174\/1574887116666210201110507","article-title":"The clinical difference between gabapentin and pregabalin: data from a pilot comparative trial","volume":"16","author":"Gammoh","year":"2021","journal-title":"Rev Recent Clin Trials"},{"key":"B20","first-page":"844","article-title":"Pharmacologic management of chronic neuropathic pain: review of the Canadian pain society consensus statement","volume":"63","author":"Mu","year":"2017","journal-title":"Can Fam Physician"},{"key":"B21","doi-asserted-by":"publisher","first-page":"229","DOI":"10.11124\/JBISRIR-D-19-00355","article-title":"PREMS and PROMS data within the acute health care context: a scoping review protocol","volume":"19","author":"Kynoch","year":"2021","journal-title":"JBI Evid Synth"},{"key":"B22","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br Med J"},{"key":"B23","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: a measure of health status from the EuroQol group","volume":"33","author":"Rabin","year":"2001","journal-title":"Ann Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2050312116671725","DOI":"10.1177\/2050312116671725","article-title":"SF-36 total score as a single measure of health-related quality of life: scoping review","volume":"4","author":"Lins","year":"2016","journal-title":"SAGE Open Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J Surg"},{"key":"B26","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019"},{"key":"B27","doi-asserted-by":"publisher","first-page":"490","DOI":"10.3923\/ijp.2012.490.495","article-title":"The effectiveness and cost-effectiveness of pregabalin in the treatment of diabetic peripheral neuropathy: a systematic review and economic model","volume":"8","author":"Meshkini","year":"2012","journal-title":"Int J Pharmacol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/jcpt.12167","article-title":"Efficacy and safety of gabapentin 1800\u2005mg treatment for post-herpetic neuralgia: a meta-analysis of randomized controlled trials","volume":"39","author":"Fan","year":"2014","journal-title":"J Clin Pharm Ther"},{"key":"B29","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jclinepi.2012.08.001","article-title":"GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s40261-013-0080-2","article-title":"Cross-over, open-label trial of the effects of gabapentin versus pregabalin on painful peripheral neuropathy and health-related quality of life in haemodialysis patients","volume":"33","author":"Atalay","year":"2013","journal-title":"Clin Drug Investig"},{"key":"B31","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/1471-2377-13-56","article-title":"Pregabalin versus gabapentin in the management of peripheral neuropathic pain associated with post-herpetic neuralgia and diabetic neuropathy: a cost effectiveness analysis for the Greek healthcare setting","volume":"13","author":"Athanasakis","year":"2013","journal-title":"BMC Neurol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/j.clinthera.2007.08.019","article-title":"A retrospective evaluation of the use of gabapentin and pregabalin in patients with postherpetic neuralgia in usual-care settings","volume":"29","author":"Gore","year":"2007","journal-title":"Clin Ther"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1111\/ijcp.12452","article-title":"Comparative safety and tolerability of duloxetine vs. pregabalin vs. duloxetine plus gabapentin in patients with diabetic peripheral neuropathic pain","volume":"68","author":"Irving","year":"2014","journal-title":"Int J Clin Pract"},{"key":"B34","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1177\/1049909111412539","article-title":"A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study","volume":"29","author":"Mishra","year":"2012","journal-title":"Am J Hosp Palliat Care"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1185\/030079907X233151","article-title":"Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia","volume":"23","author":"Rodr\u00edguez","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1111\/j.1365-2753.2011.01752.x","article-title":"Cost analysis of adding pregabalin or gabapentin to the management of community-treated patients with peripheral neuropathic pain","volume":"18","author":"Sicras-Mainar","year":"2012","journal-title":"J Eval Clin Pract"},{"key":"B37","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/j.1526-4637.2009.00796.x","article-title":"Substitution of gabapentin therapy with pregabalin therapy in neuropathic pain due to peripheral neuropathy","volume":"11","author":"Toth","year":"2010","journal-title":"Pain Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/YIC.0b013e328350b133","article-title":"Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment","volume":"27","author":"Rickels","year":"2012","journal-title":"Int Clin Psychopharmacol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/YIC.0b013e32831d7980","article-title":"Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial","volume":"24","author":"Kasper","year":"2009","journal-title":"Int Clin Psychopharmacol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/01.ajp.0000210956.31997.89","article-title":"Health and quality of life associated with chronic pain of predominantly neuropathic origin in the community","volume":"23","author":"Smith","year":"2007","journal-title":"Clin J Pain"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.3899\/jrheum.141196","article-title":"Efficacy and safety of pregabalin in patients with fibromyalgia and comorbid depression taking concurrent antidepressant medication: a randomized, placebo-controlled study","volume":"42","author":"Arnold","year":"2015","journal-title":"J Rheumatol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1177\/0269881108094722","article-title":"Early onset anxiolytic efficacy after a single dose of pregabalin: double-blind, placebo- and active-comparator controlled evaluation using a dental anxiety model","volume":"23","author":"Nutt","year":"2009","journal-title":"J Psychopharmacol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.eplepsyres.2008.07.004","article-title":"Reduction of secondarily generalized tonic-clonic (SGTC) seizures with pregabalin","volume":"82","author":"Briggs","year":"2008","journal-title":"Epilepsy Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.hoc.2018.01.005","article-title":"Cancer-related neuropathic pain: review and selective topics","volume":"32","author":"Davis","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1097\/ALN.0000000000000017","article-title":"Pregabalin rectifies aberrant brain chemistry, connectivity, and functional response in chronic pain patients","volume":"119","author":"Harris","year":"2013","journal-title":"Anesthesiology"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1111\/jdi.13815","article-title":"Prevalence and risk factors for diabetic peripheral neuropathy, neuropathic pain and foot ulceration in the Arabian gulf region","volume":"13","author":"Ponirakis","year":"2022","journal-title":"J Diabetes Investig"},{"key":"B47","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jdiacomp.2016.03.019","article-title":"Glycemic and serum lipid control in patients with painful diabetic peripheral neuropathy treated with pregabalin","volume":"31","author":"Parsons","year":"2017","journal-title":"J Diabetes Complications"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.2174\/1871530319666190306095532","article-title":"Pregabalin ameliorates lipopolysaccharide-induced pancreatic inflammation in aged rats","volume":"19","author":"Ozmen","year":"2019","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"B49","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1177\/1098612X19830501","article-title":"Changes in the stress markers cortisol and glucose before and during intradermal testing in cats after single administration of pre-appointment gabapentin","volume":"22","author":"Hudec","year":"2020","journal-title":"J Feline Med Surg"},{"key":"B50","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1177\/0897190020961229","article-title":"Patient case report: gabapentin-induced hypoglycemia","volume":"35","author":"Hayes","year":"2022","journal-title":"J Pharm Pract"},{"key":"B51","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s40263-019-00660-0","article-title":"Opioid-induced tolerance and hyperalgesia","volume":"33","author":"Mercadante","year":"2019","journal-title":"CNS Drugs"},{"key":"B52","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1097\/ALN.0000000000002648","article-title":"\u03b12\u03b4-1-bound N-methyl-D-aspartate receptors mediate morphine-induced hyperalgesia and analgesic tolerance by potentiating glutamatergic input in rodents","volume":"130","author":"Deng","year":"2019","journal-title":"Anesthesiology"},{"key":"B53","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s12031-014-0262-2","article-title":"Gabapentin enhances the morphine anti-nociceptive effect in neuropathic pain via the interleukin-10-heme oxygenase-1 signalling pathway in rats","volume":"54","author":"Bao","year":"2014","journal-title":"J Mol Neurosci"},{"key":"B54","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1471-2377-9-6","article-title":"Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain","volume":"9","author":"Quilici","year":"2009","journal-title":"BMC Neurol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1097\/j.pain.0000000000000143","article-title":"Imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial","volume":"156","author":"Holbech","year":"2015","journal-title":"Pain"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1016\/j.pain.2013.05.043","article-title":"Duloxetine and pregabalin: high-dose monotherapy or their combination? The \u201cCOMBO-DN study\u201d\u2013a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain","volume":"154","author":"Tesfaye","year":"2013","journal-title":"Pain"},{"key":"B57","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/S0140-6736(22)01472-6","article-title":"Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomised crossover trial","volume":"400","author":"Tesfaye","year":"2022","journal-title":"Lancet"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1056\/NEJMoa042580","article-title":"Morphine, gabapentin, or their combination for neuropathic pain","volume":"352","author":"Gilron","year":"2005","journal-title":"N Engl J Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1111\/j.1526-4637.2008.00423.x","article-title":"Pregabalin in the treatment of refractory neuropathic pain: results of a 15-month open-label trial","volume":"9","author":"Stacey","year":"2008","journal-title":"Pain Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/j.2040-1124.2011.00122.x","article-title":"Efficacy and safety evaluation of pregabalin treatment over 52\u00b0 weeks in patients with diabetic neuropathic pain extended after a double-blind placebo-controlled trial","volume":"2","author":"Satoh","year":"2011","journal-title":"J Diabetes Investig"},{"key":"B61","first-page":"961","article-title":"[Long-term efficacy and safety of pregabalin in patients with postherpetic neuralgia: results of a 52-week, open-label, flexible-dose study]","volume":"59","author":"Ogawa","year":"2010","journal-title":"Masui"},{"key":"B62","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/00002508-200203000-00007","article-title":"Long-term use of gabapentin for treatment of pain after traumatic spinal cord injury","volume":"18","author":"Putzke","year":"2002","journal-title":"Clin J Pain"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1111\/acer.14408","article-title":"Safety of gabapentin prescribed for any indication in a large clinical cohort of 571,718 US veterans with and without alcohol use disorder","volume":"44","author":"Rentsch","year":"2020","journal-title":"Alcohol Clin Exp Res"},{"key":"B64","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1146\/annurev-pharmtox-010617-052534","article-title":"The opioid epidemic: crisis and solutions","volume":"58","author":"Skolnick","year":"2018","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1111\/j.1440-1797.2012.01655.x","article-title":"Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: a prospective, crossover study","volume":"17","author":"Solak","year":"2012","journal-title":"Nephrology (Carlton)"},{"key":"B66","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.neurol.2020.01.361","article-title":"Pharmacological and non-pharmacologicaltreatments for neuropathic pain: systematic review and French recommendations","volume":"176","author":"Moisset","year":"2020","journal-title":"Rev Neurol (Paris)"},{"key":"B67","doi-asserted-by":"publisher","first-page":"102276","DOI":"10.1016\/j.semerg.2024.102276","article-title":"Limitaciones, controversias y desaf\u00edos de las gu\u00edas de pr\u00e1ctica cl\u00ednica sobre el manejo farmacol\u00f3gico del dolor neurop\u00e1tico [limitations, controversies and challenges of clinical practice guidelines on the pharmacological management of neuropathic pain]","volume":"50","author":"Alc\u00e1ntara Montero","year":"2024","journal-title":"Semergen"}],"container-title":["Frontiers in Pain Research"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpain.2024.1513597\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T02:19:24Z","timestamp":1736216364000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpain.2024.1513597\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,7]]},"references-count":67,"alternative-id":["10.3389\/fpain.2024.1513597"],"URL":"https:\/\/doi.org\/10.3389\/fpain.2024.1513597","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fpain.2024.1513597.s001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fpain.2024.1513597.s002","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fpain.2024.1513597.s003","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fpain.2024.1513597.s004","asserted-by":"subject"}]},"ISSN":["2673-561X"],"issn-type":[{"value":"2673-561X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,7]]},"article-number":"1513597"}}